Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapansutrile in NYHA II-III Systolic Heart Failure
NCT03534297Phase 1Completed
- Sponsor
- Olatec Therapeutics LLC
- Start
- May 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing Dapansutrile with Placebo (2 arms). Primary endpoint: Adverse events at 42 days. Started May 2018; status: completed.
02
Drugs
dapansutrile
Beyond the preview
Go deeper on NCT03534297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03534297.